The long road to neuroprotection for Parkinson's disease
- PMID: 38101888
- DOI: 10.1016/S1474-4422(23)00462-3
The long road to neuroprotection for Parkinson's disease
Conflict of interest statement
BM reports receiving honoraria for consultancy or educational presentations from General Electric Healthcare, Bial, Roche, Biogen, AbbVie, and Amprion; being a member of the executive steering committee of the Parkinson's Progression Markers Initiative (PPMI) of the Michael J Fox Foundation for Parkinson's Research (MJFF); and receiving research funding from MJFF and Aligning Science Across Parkinson's. CT reports receiving honoraria for consultancy from AbbVie, Boehringer, Roche, Britannia, Ono, Convatec, and UCB; receiving honoraria for educational lectures from AbbVie, Bial, and Alexion; receiving research funding for the PPMI of MJFF, EU (Horizon 2020), and ERA-NET BRAVA; and receiving stipends from the International Parkinson and Movement Disorder Society.
Comment on
-
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.Lancet Neurol. 2024 Jan;23(1):37-45. doi: 10.1016/S1474-4422(23)00378-2. Lancet Neurol. 2024. PMID: 38101901 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
